ROHSTOFF INTERNATIONAL

9:30 | 27.05.2015
DIAGNOS Announces a Strategic Alliance With the Largest Private Hospital Group in Latin America to Unburden Diabetes in the Public Health System

BROSSARD, QUEBEC–(Marketwired – May 27, 2015) – DIAGNOS Inc. (“DIAGNOS” or “the Corporation”) (TSX VENTURE:ADK), leader in healthcare technical services including screening, software and algorithm development, data analysis, and image processing, announces today a strategic alliance with Centro Diagnostico Angeles.

Centro Diagnostico Angeles, part of Grupo Angeles Servicios de Salud, is a diagnostic center located in Mexico City, created to outsource health services for main public health institutions in the country. The center is part of a network of private healthcare services that includes 15,000 physician specialists with a total of 55 medical specialties. They were established in 1986 and focus on technological advancement in their services while maintaining high quality patient experiences and services.

“Through this alliance, Centro Diagnostico Angeles, recognizing the power of CARA (Computer Assisted Retinal Analysis), plans to provide retina screening services for the national diabetes program run by the main public health institution in Mexico: IMSS. To begin, DIAGNOS will screen 16,000 patients in an 18 month period. Based on the results of this pilot, the screening program may be extended in both length and number of patients, with a target of opening at least three more points of service within Mexico City,” said Mr. Guillermo Moreno, Director of Business Development at DIAGNOS.

“Approximately 0.1% of an unscreened diabetic population will go blind each year, and our screening solution will help to avoid at least 85% of these blindness cases. Each patient who retains their sight and avoids chronic complications caused by diabetes represents a yearly cost savings for the Mexican public health institution of $300,000 pesos MXN (approximately 20,000 USD),” added Mr. Moreno.

About DIAGNOS

Founded in 1998, DIAGNOS is a publicly traded Canadian corporation with a mission to commercialize technologies combining contextual imaging and traditional data mining thereby improving decision making processes. DIAGNOS offers products, services, and solutions to clients in a variety of fields including healthcare and natural resources.

CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (POC) and comprises: image upload, image enhancement automated pre-screening, grading by a specialist, and referral to a specialist. CARA’s image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients, in real-time and has been approved by regulatory authorities including Health Canada, US Food and Drug Administration, and the European Union.

Forward-looking information

This document contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these
statements.

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

FOR FURTHER INFORMATION PLEASE CONTACT:
DIAGNOS Inc.
Andre Larente
President and CEO
1-877-678-8882 or (450) 678-8882, ext.: 224
alarente@diagnos.ca


NEWSLETTER

Abonnieren Sie jetzt unseren
aktuellen Newsletter

WIRTSCHAFTSNACHRICHTEN

06:11 Uhr | 23.11.2017
Lindner schließt ...


05:59 Uhr | 23.11.2017
Regierungsberater empfehlen Quote ...


05:58 Uhr | 23.11.2017
Tönnies trennt sich von ...


05:58 Uhr | 23.11.2017
Tönnies trennt sich von ...


05:57 Uhr | 23.11.2017
IG Metall kündigt Proteste gegen ...